BRPI0005616B8 - 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento - Google Patents

2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento

Info

Publication number
BRPI0005616B8
BRPI0005616B8 BRPI0005616A BRPI0005616A BRPI0005616B8 BR PI0005616 B8 BRPI0005616 B8 BR PI0005616B8 BR PI0005616 A BRPI0005616 A BR PI0005616A BR PI0005616 A BRPI0005616 A BR PI0005616A BR PI0005616 B8 BRPI0005616 B8 BR PI0005616B8
Authority
BR
Brazil
Prior art keywords
isobutyramide
morpholin
pyridin
tolyl
trifluoromethyl
Prior art date
Application number
BRPI0005616A
Other languages
English (en)
Portuguese (pt)
Inventor
Sleight Andrew
Andrew Higgins Guy
Maria Poli Sonia
Maria Ballard Theresa
Hoffmann Torsten
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0005616A publication Critical patent/BR0005616A/pt
Publication of BRPI0005616B1 publication Critical patent/BRPI0005616B1/pt
Publication of BRPI0005616B8 publication Critical patent/BRPI0005616B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0005616A 1999-11-29 2000-11-28 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento BRPI0005616B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29
EP99123685.2 1999-11-29

Publications (3)

Publication Number Publication Date
BR0005616A BR0005616A (pt) 2001-07-17
BRPI0005616B1 BRPI0005616B1 (pt) 2017-12-12
BRPI0005616B8 true BRPI0005616B8 (pt) 2021-07-06

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0005616A BRPI0005616B8 (pt) 1999-11-29 2000-11-28 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento

Country Status (49)

Country Link
EP (1) EP1103545B1 (enExample)
JP (1) JP3480835B2 (enExample)
KR (1) KR100390117B1 (enExample)
CN (1) CN1152016C (enExample)
AR (1) AR033659A1 (enExample)
AT (1) ATE253561T1 (enExample)
AU (1) AU775292B2 (enExample)
BG (1) BG64622B1 (enExample)
BR (1) BRPI0005616B8 (enExample)
CA (1) CA2326529C (enExample)
CO (1) CO5251405A1 (enExample)
CZ (1) CZ299286B6 (enExample)
DE (2) DE60006340T2 (enExample)
DK (1) DK1103545T3 (enExample)
DO (1) DOP2000000106A (enExample)
EA (1) EA004404B1 (enExample)
ES (2) ES2208205T3 (enExample)
FR (1) FR2801590A1 (enExample)
GB (1) GB2356863A (enExample)
GC (1) GC0000151A (enExample)
GE (1) GEP20022763B (enExample)
GT (1) GT200000197A (enExample)
HR (1) HRP20000809A2 (enExample)
HU (1) HU224703B1 (enExample)
ID (1) ID28483A (enExample)
IL (1) IL139868A (enExample)
IS (1) IS2212B (enExample)
IT (1) IT1320120B1 (enExample)
JO (1) JO2298B1 (enExample)
MA (1) MA26754A1 (enExample)
MX (1) MXPA00011672A (enExample)
MY (1) MY127426A (enExample)
NO (1) NO317264B1 (enExample)
NZ (1) NZ508386A (enExample)
OA (1) OA11513A (enExample)
PA (1) PA8507201A1 (enExample)
PE (1) PE20010901A1 (enExample)
PL (1) PL195957B1 (enExample)
PT (1) PT1103545E (enExample)
SG (1) SG97171A1 (enExample)
SI (1) SI1103545T1 (enExample)
SK (1) SK285373B6 (enExample)
SV (1) SV2002000227A (enExample)
TN (1) TNSN00226A1 (enExample)
TR (1) TR200302077T4 (enExample)
UA (1) UA70326C2 (enExample)
UY (1) UY26458A1 (enExample)
YU (1) YU73400A (enExample)
ZA (1) ZA200006964B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
KR20040077910A (ko) * 2002-01-31 2004-09-07 에프. 호프만-라 로슈 아게 프리프로타키키닌 유전자의 유전자 다형성
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) * 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
IL139868A0 (en) 2002-02-10
IL139868A (en) 2009-09-01
PL344147A1 (en) 2001-06-04
AR033659A1 (es) 2004-01-07
KR20010051983A (ko) 2001-06-25
GB2356863A (en) 2001-06-06
PA8507201A1 (es) 2002-02-21
CN1152016C (zh) 2004-06-02
GB0028566D0 (en) 2001-01-10
TR200302077T4 (tr) 2004-01-21
PL195957B1 (pl) 2007-11-30
EP1103545A1 (en) 2001-05-30
SK285373B6 (sk) 2006-12-07
AU7178700A (en) 2001-05-31
HU0004725D0 (enExample) 2001-02-28
JO2298B1 (en) 2005-09-12
HRP20000809A2 (en) 2001-12-31
MA26754A1 (fr) 2004-12-20
BRPI0005616B1 (pt) 2017-12-12
YU73400A (sh) 2003-02-28
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
ZA200006964B (en) 2001-06-05
JP3480835B2 (ja) 2003-12-22
HUP0004725A2 (hu) 2002-04-29
GT200000197A (es) 2002-05-22
NO20006012D0 (no) 2000-11-28
DOP2000000106A (es) 2002-07-30
ATE253561T1 (de) 2003-11-15
HU224703B1 (en) 2006-01-30
DK1103545T3 (da) 2004-03-15
ES2208205T3 (es) 2004-06-16
NO20006012L (no) 2001-05-30
JP2001151754A (ja) 2001-06-05
NO317264B1 (no) 2004-09-27
BR0005616A (pt) 2001-07-17
ES2171134A1 (es) 2002-08-16
ID28483A (id) 2001-05-31
OA11513A (fr) 2004-02-03
PE20010901A1 (es) 2001-09-20
ITMI20002575A1 (it) 2002-05-29
MY127426A (en) 2006-11-30
GEP20022763B (en) 2002-08-26
EA200001114A2 (ru) 2001-08-27
SK17932000A3 (sk) 2001-11-06
UA70326C2 (en) 2004-10-15
CZ299286B6 (cs) 2008-06-04
UY26458A1 (es) 2001-05-31
CO5251405A1 (es) 2003-02-28
TNSN00226A1 (fr) 2002-05-30
DE60006340D1 (de) 2003-12-11
SI1103545T1 (en) 2004-02-29
SG97171A1 (en) 2003-07-18
CA2326529A1 (en) 2001-05-29
CN1297888A (zh) 2001-06-06
HK1036759A1 (en) 2002-01-18
AU775292B2 (en) 2004-07-29
CZ20004399A3 (cs) 2001-07-11
SV2002000227A (es) 2002-02-05
FR2801590A1 (fr) 2001-06-01
BG64622B1 (bg) 2005-09-30
BG104992A (en) 2001-11-30
EP1103545B1 (en) 2003-11-05
NZ508386A (en) 2003-02-28
CA2326529C (en) 2009-12-22
KR100390117B1 (ko) 2003-07-04
MXPA00011672A (es) 2002-08-20
IT1320120B1 (it) 2003-11-18
IS2212B (is) 2007-02-15
PT1103545E (pt) 2004-03-31
IS5725A (is) 2001-05-29
EA004404B1 (ru) 2004-04-29
DE10058310A1 (de) 2001-05-31
EA200001114A3 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
BR0005616A (pt) 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-i l-4-o-tolil-piridin-3-il)-isobutiramida
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
SE0102299D0 (sv) Compounds
SE0102300D0 (sv) Compounds
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
BR0111116A (pt) Imitadores de trombopoietina
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0206588A (pt) Composto, processo para produzir o mesmo, uso do mesmo, composição farmacêutica, e, método para tratar um paciente afligido com uma condição patológica suscetìvel à melhora pelo antagonismo de integrinas alfa4beta1 e/ou alfa4beta7
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
ATE386725T1 (de) Heterocyclylverbindungen
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
ATE330928T1 (de) Substituierte chalkone als arzneimitteln
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/12/2017, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2698 DE 20-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.